LLY

780.02

-0.07%↓

JNJ

154.17

+1.26%↑

NVO

68.38

-1.18%↓

UNH

320.16

+4.21%↑

NVS

122.44

+1.64%↑

LLY

780.02

-0.07%↓

JNJ

154.17

+1.26%↑

NVO

68.38

-1.18%↓

UNH

320.16

+4.21%↑

NVS

122.44

+1.64%↑

LLY

780.02

-0.07%↓

JNJ

154.17

+1.26%↑

NVO

68.38

-1.18%↓

UNH

320.16

+4.21%↑

NVS

122.44

+1.64%↑

LLY

780.02

-0.07%↓

JNJ

154.17

+1.26%↑

NVO

68.38

-1.18%↓

UNH

320.16

+4.21%↑

NVS

122.44

+1.64%↑

LLY

780.02

-0.07%↓

JNJ

154.17

+1.26%↑

NVO

68.38

-1.18%↓

UNH

320.16

+4.21%↑

NVS

122.44

+1.64%↑

Search

AbbVie Inc

Open

SectorHealthcare

185.47 0.43

Overview

Share price change

24h

Current

Min

184.02

Max

186.18

Key metrics

By Trading Economics

Income

1.3B

1.3B

Sales

-1.8B

13B

P/E

Sector Avg

79.528

50.291

EPS

2.46

Dividend yield

3.54

Profit margin

9.66

Employees

55,000

EBITDA

3.2B

3.7B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+16.72% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.54%

2.40%

Next Earnings

31 Jul 2025

Next Dividend date

15 Aug 2025

Next Ex Dividend date

15 Jul 2025

Market Stats

By TradingEconomics

Market Cap

-16B

327B

Previous open

185.04

Previous close

185.47

News Sentiment

By Acuity

38%

62%

130 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

AbbVie Inc Chart

Past performance is not a reliable indicator of future results.

Related News

30 Jun 2025, 13:02 UTC

Acquisitions, Mergers, Takeovers

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion in Cash

25 Apr 2025, 13:57 UTC

Earnings

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised -- Update

25 Apr 2025, 12:52 UTC

Earnings

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised

9 Apr 2025, 18:18 UTC

Major Market Movers

Pharma Shares Reverse Losses After Tariff Pause

9 Apr 2025, 09:39 UTC

Major Market Movers

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

30 Jun 2025, 12:47 UTC

Acquisitions, Mergers, Takeovers

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1B in Cash

30 Jun 2025, 12:33 UTC

Acquisitions, Mergers, Takeovers

AbbVie Will Acquire Capstan, Including CPTX2309, a Potential First-In-Class in Vivo tLNP anti-CD19 CAR-T Therapy Candidate >ABBV

30 Jun 2025, 12:33 UTC

Acquisitions, Mergers, Takeovers

AbbVie : Proposed Acquisition Strengthens Commitment to Transforming Patient Care With Capstan's Innovative tLNP Platform Technology >ABBV

30 Jun 2025, 12:32 UTC

Acquisitions, Mergers, Takeovers

AbbVie Will Pay Up to $2.1B in Cash at Closing to Acquire Capstan >ABBV

30 Jun 2025, 12:31 UTC

Acquisitions, Mergers, Takeovers

AbbVie To Acquire Capstan Therapeutics, Further Strengthening Commitment To Transforming Patient Care In Immunology >ABBV

7 May 2025, 09:30 UTC

Top News

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

28 Apr 2025, 12:44 UTC

Earnings

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

28 Apr 2025, 09:33 UTC

Earnings

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25 Apr 2025, 16:03 UTC

Earnings

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25 Apr 2025, 14:00 UTC

Top News
Earnings

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 Apr 2025, 12:24 UTC

Top News
Earnings

AbbVie Stock Jumps as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 Apr 2025, 12:03 UTC

Top News
Earnings

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25 Apr 2025, 11:43 UTC

Earnings

AbbVie 1Q U.S. HUMIRA Rev $744M >ABBV

25 Apr 2025, 11:43 UTC

Earnings

AbbVie 1Q International HUMIRA Rev $377M >ABBV

25 Apr 2025, 11:43 UTC

Earnings

AbbVie 1Q Global Skyrizi Rev $3.43B >ABBV

25 Apr 2025, 11:43 UTC

Earnings

AbbVie 1Q Net $1.29B >ABBV

25 Apr 2025, 11:43 UTC

Earnings

AbbVie 1Q Global Net Rev From Oncology Portfolio $1.63B >ABBV

25 Apr 2025, 11:43 UTC

Earnings

AbbVie 1Q Global IMBRUVICA Rev $738M >ABBV

25 Apr 2025, 11:43 UTC

Earnings

AbbVie 1Q EPS 72c >ABBV

25 Apr 2025, 11:43 UTC

Earnings

AbbVie 1Q Adj EPS $2.46 >ABBV

25 Apr 2025, 11:43 UTC

Earnings

AbbVie 1Q Rev $13.34B >ABBV

25 Apr 2025, 11:43 UTC

Earnings

AbbVie Sees FY Adj EPS $12.09-Adj EPS $12.29 >ABBV

14 Mar 2025, 09:30 UTC

Top News

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

3 Mar 2025, 15:04 UTC

Acquisitions, Mergers, Takeovers

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. -- IBD

28 Feb 2025, 12:00 UTC

Top News

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

Peer Comparison

Price change

AbbVie Inc Forecast

Price Target

By TipRanks

16.72% upside

12 Months Forecast

Average 212.8 USD  16.72%

High 250 USD

Low 170 USD

Based on 17 Wall Street analysts offering 12 month price targets forAbbVie Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

17 ratings

11

Buy

6

Hold

0

Sell

Technical Score

By Trading Central

180.37 / 195.54Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

130 / 380 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.